Advertisement


Lori Pierce, MD, on Breast Cancer Radiotherapy: Late Side Effects

2015 San Antonio Breast Cancer Symposium

Advertisement

Lori J. Pierce, MD, of the University of Michigan Health System, discusses findings on second cancer incidence and non-breast cancer mortality among 40,000 women in 75 clinical trials. (Abstract S5-08)



Related Videos

Breast Cancer

Lisa Carey, MD, and Sibylle Loibl, MD, PhD: Update on Metastatic Disease

Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy, and brain metastases (Abstract YR4).

Breast Cancer

Gunter von Minckwitz, MD: Early Survival Analysis of GeparSixto

Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).

Breast Cancer

Andrew Seidman, MD, and Norman Wolmark, MD, on NSABP Clinical Trials and Management of Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)

Breast Cancer

Andrew Seidman, MD, and Hope Rugo, MD: Less is More: Scaling Back Breast Cancer Treatment

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalating systemic therapy for breast cancer (Abstract ES6-3).

Breast Cancer

Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen

Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)

Advertisement

Advertisement




Advertisement